Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aspira Pathlab & DiagnosticsBOM:540788 -1.97%51 PB Ratio is 9.00 as of Aug. 08, 2026, which is 45% above its 10-year median of 6.21. GuruFocus rates BOM:540788 with a GF Score™ of 51/100 and a GF Value™ of ₹70.73 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 195 Medical Diagnostics & Research companies, Aspira Pathlab & Diagnostics ranks worse than 87.69% on this metric.
The historical rank and industry rank for Aspira Pathlab & Diagnostics's PB Ratio or its related term are showing as below:
BOM:540788'
s PB Ratio Range Over the Past 10 Years
Min: 3.18 Med: 6.21 Max: 109.09
Current: 9.19
During the past 13 years, Aspira Pathlab & Diagnostics's highest PB Ratio was 109.09. The lowest was 3.18. And the median was 6.21.
BOM:540788's PB Ratio is ranked worse than 87.69% of 195
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.11
vs BOM:540788: 9.19
During the past 12 months, Aspira Pathlab & Diagnostics's average Book Value Per Share Growth Rate was 69.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 16.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 17.90% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Aspira Pathlab & Diagnostics was 188.20% per year. The lowest was -64.30% per year. And the median was 16.10% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Aspira Pathlab & Diagnostics PB Ratio Related Terms
Aspira Pathlab & Diagnostics PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Aspira Pathlab & Diagnostics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aspira Pathlab & Diagnostics PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Pathlab & Diagnostics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Aspira Pathlab & Diagnostics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Aspira Pathlab & Diagnostics (BOM:540788) has a PB Ratio of 9.00 as of Aug. 08, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Aspira Pathlab & Diagnostics and its competitors. This is 45% above median its historical median of 6.21. Over the past decade, Aspira Pathlab & Diagnostics' PB Ratio has ranged from 3.18 to 109.09. According to the industry distribution chart, Aspira Pathlab & Diagnostics ranks #171 out of 195 companies in the Medical Diagnostics & Research industry, placing it in the top 87.7%.
Is Aspira Pathlab & Diagnostics' PB Ratio too high?
Aspira Pathlab & Diagnostics' current PB Ratio of 9.00 is 45% above median its 10-year median of 6.21. Over the past 10 years, this metric has ranged from a low of 3.18 to a high of 109.09. The Medical Diagnostics & Research industry median PB Ratio is 2.11. Aspira Pathlab & Diagnostics' value of 9.00 is 326.5% above this industry median. Based on the distribution chart, Aspira Pathlab & Diagnostics ranks #171 out of 195 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Aspira Pathlab & Diagnostics has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aspira Pathlab & Diagnostics' PB Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Aspira Pathlab & Diagnostics ranks #171 out of 195 companies for PB Ratio. This places Aspira Pathlab & Diagnostics in the lower half of its industry. The industry median PB Ratio is 2.11. Aspira Pathlab & Diagnostics' value of 9.00 is 326.5% above this benchmark. Historically, Aspira Pathlab & Diagnostics' own PB Ratio has ranged from 3.18 to 109.09 over the past decade. While the company's 10-year median is 6.21 vs. the industry median of 2.11, Aspira Pathlab & Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Diagnostics & Research company?
The median PB Ratio among Medical Diagnostics & Research companies is 2.11, based on 195 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aspira Pathlab & Diagnostics's current PB Ratio of 9.00 is 326.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Aspira Pathlab & Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median PB Ratio is 2.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aspira Pathlab & Diagnostics's current PB Ratio is 9.00, which is 45% above median its own 10-year median of 6.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspira Pathlab & Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Aspira Pathlab & Diagnostics (BOM:540788) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹70.73, compared to a current price of ₹106.90 — trading 51.1% above its estimated fair value. The current PB Ratio is 9.00, which is 45% above median its 10-year median of 6.21 and 326.5% above the Medical Diagnostics & Research industry median of 2.11. Aspira Pathlab & Diagnostics' overall GF Score™ is 51/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Aspira Pathlab & Diagnostics (BOM:540788), the current PB Ratio is 9.00 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aspira Pathlab & Diagnostics (BOM:540788) Overvalued in 2026?
Based on GuruFocus' analysis, Aspira Pathlab & Diagnostics stock appears to be overvalued.
The current stock price of ₹106.90 is trading 51.1% above its estimated GF Value™ of ₹70.73.
GuruFocus considers Aspira Pathlab & Diagnostics to be Significantly Overvalued.
Key valuation signals for BOM:540788:
PB Ratio: 9.00 (45% above median its 10-year median of 6.21)
GF Value™: ₹70.73 vs. price of ₹106.90 (51.1% above fair value)
Industry Position: 326.5% above the Medical Diagnostics & Research median (#171 of 195)
No single metric tells the full story. See the BOM:540788 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aspira Pathlab & Diagnostics Ltd is mainly engaged in pathology and related healthcare services. It operates laboratories that conduct a wide range of pathological investigations across branches such as biochemistry, hematology, histopathology, microbiology, immunochemistry, immunology, virology, cytology, and other pathological and radiological tests. The services offered include pathology tests, sonography, X-rays, and radiology. The company also provides various health packages like gynecology profiles, anemia profiles, monsoon profiles, coagulation tests, cancer screening packages, newborn screening and IEM panels, orthopedic profiles, allergy panels, and cardiac profiles. These comprehensive diagnostic services assist in disease diagnosis.
51GF Score
Get the complete analysis for BOM:540788
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540788 has been successfully added to your 
